Individuals who are carriers of hereditary pathogenic variants exhibit a higher risk (usually ≥ 50%) of developing cancers during their lifetime. These cancer-related variants are the predisposition to cancer. Therefore, early detection gives you opportunity to maximize health outcomes for your high-risk patients group with patient-tailored screening programs, preventive measures and proactive treatment.
Through one sample and one test, NovoFocus™ CR can screen the whole exon regions of the genes which are recommended by international guidelines.
Using NGS platform and unique proprietary technology, assess the SNP, InDel, and large fragment deletions at once.
Integrated internationally recognized databases to interpret data and generate report.
With top tier sequencing capacity and superior process efficiency, Novogene offers highly competitive prices for all our services.
NovoFocus™ CR contains 106 genes associated with hereditary cancers. The genes are carefully selected with the potential risks of developing one or more of the following hereditary tumors.
(*OMIM Database and NCCN Guidelines)
The field is required.